# Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)

> **NCT00659477** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 117 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT00659477
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2010-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00659477

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00659477, "Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00659477. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*